Last reviewed · How we verify

Cycvalon — Competitive Intelligence Brief

Cycvalon (CYCLOVALONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cyclovalone. Area: Immunology.

phase 2 cyclovalone Transcription factor AP-1, Nuclear factor NF-kappa-B p105 subunit, Integrase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Cycvalon (CYCLOVALONE). Cycvalon works by blocking the NF-kappa-B pathway, which helps regulate inflammation and immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cycvalon TARGET CYCLOVALONE phase 2 cyclovalone Transcription factor AP-1, Nuclear factor NF-kappa-B p105 subunit, Integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cyclovalone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cycvalon — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclovalone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing